BR112018008617A2 - cápsulas revestidas com película de libertação prolongada - Google Patents

cápsulas revestidas com película de libertação prolongada

Info

Publication number
BR112018008617A2
BR112018008617A2 BR112018008617A BR112018008617A BR112018008617A2 BR 112018008617 A2 BR112018008617 A2 BR 112018008617A2 BR 112018008617 A BR112018008617 A BR 112018008617A BR 112018008617 A BR112018008617 A BR 112018008617A BR 112018008617 A2 BR112018008617 A2 BR 112018008617A2
Authority
BR
Brazil
Prior art keywords
capsules
release film
extended release
coated capsules
prolonged release
Prior art date
Application number
BR112018008617A
Other languages
English (en)
Inventor
Mcguffy Irena
M Bell William
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of BR112018008617A2 publication Critical patent/BR112018008617A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulações farmacêuticas, de preferência na forma de cápsulas de gelatina ou cápsulas duras, que exibem liberação prolongada através do uso de um revestimento compreendendo um polímero insolúvel em água e um formador de poro independente de ph. a liberação prolongada de cápsulas de gel flexível e cápsulas de invólucro dura pode ser obtida sem o uso de materiais semi-sólidos ou sólidos à base de lipídeos.
BR112018008617A 2015-10-30 2016-10-27 cápsulas revestidas com película de libertação prolongada BR112018008617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/928,029 US20170119680A1 (en) 2015-10-30 2015-10-30 Extended release film-coated capsules
PCT/US2016/059116 WO2017075215A1 (en) 2015-10-30 2016-10-27 Extended release film-coated capsules

Publications (1)

Publication Number Publication Date
BR112018008617A2 true BR112018008617A2 (pt) 2018-10-30

Family

ID=57233954

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008617A BR112018008617A2 (pt) 2015-10-30 2016-10-27 cápsulas revestidas com película de libertação prolongada

Country Status (10)

Country Link
US (1) US20170119680A1 (pt)
EP (1) EP3368019A1 (pt)
JP (1) JP2018531985A (pt)
CN (1) CN108601743A (pt)
AU (1) AU2016344402A1 (pt)
BR (1) BR112018008617A2 (pt)
CA (1) CA3003644A1 (pt)
HK (1) HK1253677A1 (pt)
MX (1) MX2018005456A (pt)
WO (1) WO2017075215A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020044121A1 (en) * 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Oral formulations of phenylalanine and cannabinoids
SG11202101625RA (en) 2018-09-05 2021-03-30 Renapharma AB An iron containing composition and use thereof
CA3142702A1 (en) * 2019-06-03 2020-12-10 R.P. Scherer Technologies, Llc Delayed release softgel capsules
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
CA3171512A1 (en) * 2020-03-18 2022-09-23 Rickey Steve Shelley Softgel capsules
KR20230018445A (ko) * 2020-06-02 2023-02-07 알.피.쉐러 테크놀러지즈 엘엘씨 지연 방출 소프트겔 캡슐
JP2023547062A (ja) * 2020-10-16 2023-11-09 アール．ピー．シェーラー テクノロジーズ，エルエルシー 改変放出ソフトゲルカプセル
KR20240037990A (ko) * 2021-07-06 2024-03-22 알.피.쉐러 테크놀러지즈 엘엘씨 소프트겔 캡슐

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK164642C (da) 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
NL1009107C2 (nl) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel.
CA2348843A1 (en) 1998-11-11 2000-05-18 Edward Zbygniew Nowak A capsule based drug delivery system
IL143691A0 (en) 1998-12-17 2002-04-21 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20020114832A1 (en) 2000-12-11 2002-08-22 Dr. Willmar Schwabe Gmbh & Co. Pharmaceutical preparation comprising peppermint oil and caraway oil in delayed release form
WO2002087543A1 (en) 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030092765A1 (en) 2001-11-15 2003-05-15 John Kelly Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
EP1578350B1 (en) 2002-03-26 2009-05-27 Euro-Celtique S.A. Sustained-release gel coated compositions
FR2838349B1 (fr) 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050152967A1 (en) 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
JP2006526057A (ja) * 2003-04-14 2006-11-16 エフ　エム　シー　コーポレーション 均一で熱可逆性の低粘度ポリマンナンガムフィルム及びそれからつくったソフトカプセル
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005097082A1 (en) 2004-03-31 2005-10-20 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
US20090017110A1 (en) 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20070082046A1 (en) 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
CN101049380A (zh) * 2007-05-11 2007-10-10 张冰文 含有山茶油的肠溶软胶囊及其制备方法
US20090136650A1 (en) 2007-09-18 2009-05-28 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
CN103169685B (zh) * 2011-12-23 2018-03-06 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞控释制剂及其制备方法
WO2015028972A1 (en) * 2013-09-02 2015-03-05 Ranbaxy Laboratories Limited Pulsatile-release dosage form

Also Published As

Publication number Publication date
JP2018531985A (ja) 2018-11-01
WO2017075215A1 (en) 2017-05-04
HK1253677A1 (zh) 2019-06-28
AU2016344402A1 (en) 2018-05-17
CN108601743A (zh) 2018-09-28
CA3003644A1 (en) 2017-05-04
MX2018005456A (es) 2018-11-09
EP3368019A1 (en) 2018-09-05
US20170119680A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
BR112018008617A2 (pt) cápsulas revestidas com película de libertação prolongada
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
JP2018533683A5 (pt)
IL267143A (en) Benzenesulfonamide compounds and their use as therapeutic agents
TWD177195S (zh) 資訊提供終端機
AR106385A1 (es) Composición cosmética que comprende bacterias probióticas
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
ZA201807518B (en) Benzenesulfonamide compounds and their use as therapeutic agents
EP3543239A4 (en) SELECTIVE INHIBITOR OF BRUTON TYROSINE KINASE AND USE THEREOF
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
WO2016130581A8 (en) Combination cancer therapy
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
EP3401685A4 (en) DIAGNOSIS AND MEDICINE WITH ADAMTS13 AS A MAIN PART
BR112017012400A2 (pt) processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
EA201892469A1 (ru) Опорная шайба
RS53033B (en) VILDAGLIPTIN AND GLIMEPIRID COMBINATIONS
BR112017021120A2 (pt) forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
USD828874S1 (en) Gaming system volatility marker

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]